An emerging Gilead Sciences, with a specific focus on small molecule therapeutics for infectious diseases.

• Arakoda: A regulatory-approved malaria preventative treatment available on the market since late 2019.
• Celgosivir: A product currently in development for COVID-19, RSV, and Dengue.

60 Degrees Pharmaceuticals (SXTP) primarily sells its prescription pharmaceutical products, such as Arakoda, to other companies rather than directly to individuals. The provided company description does not list the names of specific customer companies. However, based on the nature of its products (a malaria preventative treatment and other infectious disease therapeutics), its major customers would typically fall into these categories:

• Government Agencies: Especially military organizations (e.g., Department of Defense or similar bodies in other countries) for use by personnel deployed in malaria-endemic regions, and potentially public health agencies or international aid organizations.
• Pharmaceutical Wholesalers and Distributors: These companies purchase drugs from manufacturers and then supply them to pharmacies, hospitals, and other healthcare providers.
• Hospitals and Pharmacies: These healthcare institutions and retail outlets procure the medication to dispense to patients requiring malaria prevention.

Geoffrey Dow, Chief Executive Officer, President, and Director

Geoffrey Dow is a co-founder of 60 Degrees Pharmaceuticals, Inc. in 2010. He has over 20 years of experience in product development for tropical diseases, including 13 years in leadership and advisory roles within the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow was instrumental in securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis.

Tyrone Miller, Chief Financial Officer and Treasurer

Tyrone Miller joined 60 Degrees Pharmaceuticals in 2014 and has served in various capacities, including Chief Financial Officer and Treasurer. He has experience raising over $6 million in external financing and establishing multinational financial reporting systems. Mr. Miller is also the founder and Principal of Miller Tax & Advisory since 2011, where he advises business owners on accounting, financial, and tax matters. He is a Certified Public Accountant.

Bryan Smith, Chief Medical Officer

Bryan Smith is a medical doctor with over 30 years of experience in governmental research and leadership, including serving as a retired military colonel. He joined 60 Degrees Pharmaceuticals in 2016 and possesses expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. Dr. Smith also holds a position as Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC, and previously served as Chief Medical Officer for Amivas LLC.

Kristen Landon, Chief Commercial Officer

Kristen Landon joined 60 Degrees Pharmaceuticals in 2024, bringing over 26 years of experience in building and transforming pharmaceutical brands. Her background includes launching and relaunching more than a dozen brands, many achieving peak revenues exceeding $100 million, across diverse therapeutic categories such as women's health, infectious disease, dermatology, nephrology, and hematology/oncology.

Jennifer Herz, Director

Jennifer Herz serves as a head consultant for 60 Degrees Pharmaceuticals and possesses over 20 years of experience in commercial, business development, and scientific affairs within the bio-pharma industry, with a particular focus on vaccines. She was the first Managing Director of Sanofi Pasteur in Australia, where she played a key role in developing the company and commercially launching five new vaccines. Ms. Herz is also a co-founder and director at Biointelect Pty.

The key risks for 60 Degrees Pharmaceuticals (SXTP) are primarily centered around the inherent challenges of pharmaceutical development and commercialization.

1. Clinical Development and Regulatory Approval Risk: The company's future growth is highly dependent on the successful development, clinical trials, and regulatory approval of its pipeline products, including new products containing Tafenoquine (the active ingredient in Arakoda) and Celgosivir. Celgosivir is explicitly stated to be "further testing the viability... to determine whether to advance it into further clinical development," indicating it is in an early and high-risk stage. The process of drug development is complex, costly, and has a high rate of failure, meaning there is significant risk that these products may not achieve regulatory approval or may take longer and cost more than anticipated.
2. Commercialization and Market Reliance on Arakoda: While Arakoda is an approved malaria preventative treatment, the company is "seeking to expand Arakoda’s use for malaria prevention and to demonstrate clinical benefit for other disease indications." This suggests that the current commercial success of Arakoda may not be sufficient to meet the company's growth objectives, and its financial performance is heavily reliant on the continued and expanded market acceptance of this single primary product. Failure to expand Arakoda's use or achieve strong market penetration could significantly impact revenue and profitability.

The addressable markets for 60 Degrees Pharmaceuticals' main products and services are detailed below:

Arakoda (Tafenoquine)

• For Malaria Prevention: The global antimalarial drugs market, which includes prevention, was valued at approximately US$ 1.07 billion in 2024 and is projected to reach around US$ 1.67 billion by 2034.
• For Human Babesiosis: 60 Degrees Pharmaceuticals estimates the maximum annual addressable market (TAM) for Arakoda for the treatment of human babesiosis in the U.S. to be 380,000 patients, generating $245 million in sales annually. The cumulative TAM through patent expiration in 2035 is projected to be 1.17 million patients, equating to $1.1 billion.

Celgosivir

• For COVID-19 Treatment: The global COVID-19 therapeutics market was valued at approximately $9.36 billion in 2024. However, this market is expected to significantly decline to $541.44 million by 2029 globally. The antiviral segment, which includes Celgosivir, accounted for $2.76 billion of the global market in 2024. The U.S. market for COVID-19 therapeutics constituted $5.09 billion in 2024.
• For RSV (Respiratory Syncytial Virus) Treatment: The global respiratory syncytial virus treatment market was valued at approximately USD 2.39 billion in 2024 and is projected to reach USD 8.33 billion by 2033. In the U.S., the demand for human RSV treatment is projected to grow from USD 674.6 million in 2025 to USD 1,342.6 million by 2035.
• For Dengue Treatment: The global dengue fever treatment market was estimated at approximately USD 2.14 billion in 2024 and is projected to grow to USD 3.86 billion by 2035. The North America dengue treatment market was valued at USD 158.10 million in 2024 and is projected to reach USD 348.19 million by 2032.

1. Expanded Sales and Marketing for Arakoda in Malaria Prevention: The company is actively expanding its commercial efforts for Arakoda, its FDA-approved malaria preventative treatment. This includes doubling the number of inside sales representatives, forming partnerships such as with GoodRx to broaden point-of-sale visibility and offer patient savings, and enhancing digital marketing campaigns to increase prescriber awareness and engagement. A new 8-count bottle format has also been released to cater to short-duration travelers, expanding access through major retail pharmacies and platforms like Amazon Pharmacy. Additionally, a partnership with Runway Health, commencing in April 2026, aims to provide international travelers with direct access to Arakoda through a telehealth platform. These initiatives are built on a commercial pilot that demonstrated increasing market demand and led to a 223% year-over-year increase in Q3 2025 net product revenue for Arakoda.
2. Expansion of Arakoda into the Babesiosis Treatment Market: 60 Degrees Pharmaceuticals is pursuing the repositioning of Arakoda (tafenoquine) for the treatment of babesiosis, a tick-borne disease currently lacking FDA-approved treatments. The company received IRB approval for a Phase II clinical study of Arakoda for chronic babesiosis, with patient enrollment expected to begin in Q3 2025. Recent expanded-use clinical trials have shown promising results, with all three enrolled patients cured of relapsing babesiosis after completing the tafenoquine regimen, suggesting a high cure rate. The company estimates a significant addressable market exceeding 400,000 patients for Arakoda in babesiosis treatment through its patent protection period. The CEO has highlighted expanding Arakoda's label to include babesiosis as a key strategy for growth and improving market valuation.
3. Advancement and Potential Commercialization of Celgosivir for Viral Diseases: The company's pipeline includes Celgosivir, which is under development for COVID-19, RSV, and Dengue. Celgosivir is currently in Phase I clinical development for Respiratory Syncytial Virus (RSV) infections. Preliminary data indicates that Celgosivir may inhibit the replication of SARS-CoV-2 (the virus causing COVID-19) and RSV in cell culture, and potentially protect the lungs from RSV infection in animal models. While its development for dengue has seen some challenges in the past, 60 Degrees Pharmaceuticals is planning a clinical development campaign for its repositioning across these viral illnesses, representing a potential long-term revenue driver as it progresses through clinical trials.

Share Issuance

• The company completed a micro-cap unit Initial Public Offering (IPO) on July 12, 2023, raising $7.5 million by offering 1.42 million units.
• On February 5, 2025, 60 Degrees Pharmaceuticals conducted a registered direct offering and concurrent private placement of common stock and warrants, generating approximately $1.075 million in gross proceeds.
• A public offering was priced on July 15, 2025, aiming to generate approximately $5 million in gross proceeds, with potential for an additional $5 million upon full exercise of associated short-term warrants.
• The company has implemented two reverse stock splits: a 1-for-5 split effective February 24, 2025, and a 1-for-4 split effective January 20, 2026, primarily to maintain compliance with Nasdaq's minimum bid price requirement.

Inbound Investments

• The company secured $7.5 million in capital from its micro-cap unit IPO on July 12, 2023.
• Approximately $5 million in gross proceeds were expected from a public offering priced on July 15, 2025, which also included accompanying warrants that could bring in up to an additional $5 million if fully exercised.
• A registered direct offering and concurrent private placement on February 5, 2025, resulted in approximately $1.075 million in gross proceeds.

Outbound Investments

• In January 2026, 60 Degrees Pharmaceuticals exercised an option to negotiate an exclusive license with Florida State University for large-scale purification techniques of castanospermine.
• The company maintains a patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.

Capital Expenditures

• Capital expenditures were approximately $60,000 in the 12 months leading up to March 8, 2026.
• In fiscal year 2024, capital expenditures amounted to $104,000.
• The company is in an investment phase, with expanding operating expenses primarily driven by clinical trial programs and research collaborations.